Latest Conference Articles

An immune checkpoint inhibitor plus ramucirumab found to improve overall survival versus standard of care in patients with advanced non-small cell lung cancer.

Ibrutinib plus bendamustine-rituximab and rituximab maintenance was found to lower the risk of disease progression or death by 25% compared with placebo in patients 65 years of age or older with newly diagnosed mantle cell lymphoma.

Uliledlimab plus toripalimab (Tuoyi) shows significant response rates in patients with advanced non–small cell lung cancer previously ineligible to receive standard-of-care treatment.

Analysis shows that different genetic mutation profiles in tumors harboring PIK3CA mutation did not affect the treatment benefit with alpelisib (Piqray) combined with fulvestrant in individuals with HR+/HER2- advanced or metastatic breast cancer.

Improvement in recurrence-free survival was seen primarily in individuals with very high-risk renal cell carcinoma, whereas individuals with intermediate high-risk disease showed no improvements in survival.

The median overall survival was 66 months for individuals with hormone receptor-positive/human epidermal growth factor receptor-negative advanced or metastatic breast cancer administered at least 1 dose reduction of ribociclib (Kisqali) from the starting dose of 600 mg.

Company releases data at the American Society of Clinical Oncology Annual Meeting 2022 showing that the drug is well-tolerated in patients with solid tumors.

Pharmacy Times will be covering the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting live in Chicago, Illinois, from June 3 through 7, 2022.

We're rowing in the same direction as pharmacists, so that what is of interest to a payer, PBMs and pharmacies, according to PQA.

Just making sure that everybody has a seat at the table is the most important thing at PQA.

PQA wants to expand the types of services covered and report on the results of the current examples that are profiled in the SDOH guide.

The challenges in pharmacy are really a lack of standardization.

Pharmacists are ideally positioned to screen patients for estimation aids and then refer them to services.

Pharmacists are an important touch point for PQA, and they're starting small and thinking big.

PQA is also committed to national goals related to HIV and reducing HIV ending the epidemic.

PQA is focused on actually testing the feasibility and implementation of some of these measures as concepts.

One example that has already been done in the past relates to understanding how to better measure insulin persistence.

Issues like medication access and transportation cost all impact a patient's ability to have access to medications and use them safely and effectively.

It's really opening up the world for pharmacists to develop more meaningful measures and get at patient reported and clinical outcome measures.

It's extremely important for pharmacists to be involved in helping care for people who have HIV.

Pharmacy performance measures allow the pharmacy to be more engaged in the patient's care that focuses on outcomes.

There are many initiatives that are going on at PQA right now that are related to health equity.

The guide is an opportunity to just catalog what else is going on there to kind of be an inspiration for expansion of services.

The goals of the pharmacy measures are ultimately to be used in value based arrangements.

There are other courses available on HIV, but PQA's surveys the 13 medication related quality measures out there for HIV.

The term "value" is used interchangeably across our healthcare system.

One of PQA's quantitative research projects that they are working on now is looking at how medication adherence is related to outcomes.

PQA's program is focused on quality measurement and improving the safe and appropriate use of medications.